Home > Research > Publications & Outputs > Riluzole-Triazole Hybrids as Novel Chemical Pro...

Research

Associated organisational unit

Links

Text available via DOI:

Keywords

View graph of relations

Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis. / Sweeney, Joseph B.; Rattray, Marcus; Pugh, Victoria et al.
In: ACS Medicinal Chemistry Letters, Vol. 9, No. 6, 14.06.2018, p. 552-556.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Sweeney, JB, Rattray, M, Pugh, V & Powell, LA 2018, 'Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis', ACS Medicinal Chemistry Letters, vol. 9, no. 6, pp. 552-556. https://doi.org/10.1021/acsmedchemlett.8b00103

APA

Sweeney, J. B., Rattray, M., Pugh, V., & Powell, L. A. (2018). Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis. ACS Medicinal Chemistry Letters, 9(6), 552-556. https://doi.org/10.1021/acsmedchemlett.8b00103

Vancouver

Sweeney JB, Rattray M, Pugh V, Powell LA. Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis. ACS Medicinal Chemistry Letters. 2018 Jun 14;9(6):552-556. Epub 2018 May 30. doi: 10.1021/acsmedchemlett.8b00103

Author

Sweeney, Joseph B. ; Rattray, Marcus ; Pugh, Victoria et al. / Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis. In: ACS Medicinal Chemistry Letters. 2018 ; Vol. 9, No. 6. pp. 552-556.

Bibtex

@article{e15c88133df049a3be5a3bc9d9c586b6,
title = "Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis",
abstract = "Despite intense attention from biomedical and chemical researchers, there are few approved treatments for amyotrophic lateral sclerosis (ALS), with only riluzole (Rilutek) and edaravone (Radicava) currently available to patients. Moreover, the mechanistic basis of the activity of these drugs is currently not well-defined, limiting the ability to design new medicines for ALS. This Letter describes the synthesis of triazole-containing riluzole analogues, and their testing in a novel neuroprotective assay. Seven compounds were identified as having neuroprotective activity, with two compounds having similar activity to riluzole.",
keywords = "Amyotrophic lateral sclerosis, motor neuron disease, primary cortical neurons, riluzole",
author = "Sweeney, {Joseph B.} and Marcus Rattray and Victoria Pugh and Powell, {Lucy A.}",
year = "2018",
month = jun,
day = "14",
doi = "10.1021/acsmedchemlett.8b00103",
language = "English",
volume = "9",
pages = "552--556",
journal = "ACS Medicinal Chemistry Letters",
publisher = "American Chemical Society",
number = "6",

}

RIS

TY - JOUR

T1 - Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis

AU - Sweeney, Joseph B.

AU - Rattray, Marcus

AU - Pugh, Victoria

AU - Powell, Lucy A.

PY - 2018/6/14

Y1 - 2018/6/14

N2 - Despite intense attention from biomedical and chemical researchers, there are few approved treatments for amyotrophic lateral sclerosis (ALS), with only riluzole (Rilutek) and edaravone (Radicava) currently available to patients. Moreover, the mechanistic basis of the activity of these drugs is currently not well-defined, limiting the ability to design new medicines for ALS. This Letter describes the synthesis of triazole-containing riluzole analogues, and their testing in a novel neuroprotective assay. Seven compounds were identified as having neuroprotective activity, with two compounds having similar activity to riluzole.

AB - Despite intense attention from biomedical and chemical researchers, there are few approved treatments for amyotrophic lateral sclerosis (ALS), with only riluzole (Rilutek) and edaravone (Radicava) currently available to patients. Moreover, the mechanistic basis of the activity of these drugs is currently not well-defined, limiting the ability to design new medicines for ALS. This Letter describes the synthesis of triazole-containing riluzole analogues, and their testing in a novel neuroprotective assay. Seven compounds were identified as having neuroprotective activity, with two compounds having similar activity to riluzole.

KW - Amyotrophic lateral sclerosis

KW - motor neuron disease

KW - primary cortical neurons

KW - riluzole

U2 - 10.1021/acsmedchemlett.8b00103

DO - 10.1021/acsmedchemlett.8b00103

M3 - Journal article

AN - SCOPUS:85047982692

VL - 9

SP - 552

EP - 556

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

IS - 6

ER -